Risk factors for intrahepatic recurrence after curative surgical treatment of colorectal liver metastases.

Background/aim: Hepatic resection has been regarded as the only curative treatment for colorectal liver metastases. After a first hepatectomy, 30% to 70% of patients develop intrahepatic recurrence. In this study, we retrospectively analyzed risk factors for intrahepatic recurrence.

A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.

Purpose: The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer.

Methods: S-1 was administered orally at 80 mg/m(2) per day for 14 consecutive days followed by a 2-week rest. CPT-11 was given intravenously on days 1 and 15 of each course, at an initial dose of 80 mg/m(2) per day, stepping up to 100, 120 or 150 mg/m(2) per day.

Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases.

Cholangiocarcinoma is a therapeutically challenging malignancy. This report describes a case where the patient received multimodal therapy, including surgery, adjuvant chemoradiation therapy, and combination chemotherapy and successfully achieved long-term survival. Specifically, the patient achieved an extended complete response after combination chemotherapy with TS-1 (an orally administered drug that is a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine [CDHP], and oteracil potassium [Oxo]) and cisplatin for recurrence.

[A resected case of metastatic pancreatic cancer from cecal carcinoma].

A 64-year-old woman underwent an ileocecectomy in July 2002 for ruptured cecal carcinoma, which was a well-differentiated adenocarcinoma, stage II, ss, ly0, v0, n (-). In August 2005, abdominal CT revealed a tumor 20mm in diameter in the pancreatic tail, therefore, a distal pancreatectomy and splenectomy were performed. The pancreatic tumor resembled the moderately differentiated cecal adenocarcinoma, both having p53 and k-ras point mutations in common, and it was diagnosed as a metastasis of the cecal carcinoma.

[Case of GIST of the rectum successfully treated with imatinib mesylate neoadjuvant therapy].

A 60-year-old man, with a high risk GIST of the rectum, suspected of the infiltration to the prostate and measuring 10 cm in diameter, underwent resection after neoadjuvant therapy of imatinib mesylate. Perineal approach was added because intraperitoneal dissection was not enough, however, the infiltration to the prostate was denied completely due to a reduction in the tumor size, thus total peritoneal resection was avoided. It seems that neoadjuvant therapy with imatinib mesylate is useful for resectability and for the preservation of the functions of ambient organs.